Literature DB >> 33555573

Tolvaptan-induced remission of primary palmar hyperhidrosis in a patient with ADPKD: a serendipitous finding.

E Cuka1, M Vespa2, G Joli2, P Manunta2, T M Sciarrone Alibrandi2.   

Abstract

A 37-year old man had suffered palmar hyperhidrosis since he was fifteen years old. In the last year, he has been treated with tolvaptan for autosomic polycystic kidney disease (ADPKD). The start of tolvaptan therapy was associated with a complete resolution of palmar hyperhidrosis and a sensation of relaxation. During the year on which the patient took tolvaptan, he had to suspend the drug twice. The suspension of tolvaptan was associated with the reappearance of palmar hyperhidrosis followed by sudden remission after the drug reintroduction. Palmar sweating also known as 'emotional sweating' is not related to thermoregulation but allows an adequate adjustment of the frictional force to perform fine hand movements. Palmar hyperhidrosis is a chronic neurologic disorder characterized by excessive sweating of eccrine glands due to overactivity of the sympathetic nervous system. Palmar sweating and emotional processing are controlled by the limbic system. In this case report reduction of palmar sweating was associated with a sense of well-being. Corticotropin releasing factor (CRF) and adrenocorticotropic hormone (ACTH) are the two main hypothalamic hormones that interact with both the limbic system and the peripheral sympathetic nervous system. Tolvaptan is an arginine vasopressin (AVP) antagonist. AVP has effects on the sympathetic nervous system through both central and peripheral actions. Centrally AVP is a well-known ACTH secretagogue. Remission of palmar hyperhidrosis is probably mediated by tolvaptan acting on central ACTH secretion.
© 2021. Italian Society of Nephrology.

Entities:  

Keywords:  ADPKD; Arginine vasopressin; Palmar hyperhidrosis; Tolvaptan; Vasopressin antagonists

Mesh:

Substances:

Year:  2021        PMID: 33555573     DOI: 10.1007/s40620-021-00973-8

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  7 in total

1.  A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications.

Authors:  R M Luque; A Ibáñez-Costa; L M López-Sánchez; L Jiménez-Reina; E Venegas-Moreno; M A Gálvez; A Villa-Osaba; A M Madrazo-Atutxa; M A Japón; A de la Riva; D A Cano; P Benito-López; A Soto-Moreno; M D Gahete; A Leal-Cerro; J P Castaño
Journal:  J Clin Endocrinol Metab       Date:  2013-07-24       Impact factor: 5.958

Review 2.  Vasopressin antagonists.

Authors:  Tomas Berl
Journal:  N Engl J Med       Date:  2015-06-04       Impact factor: 91.245

3.  Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors.

Authors:  P L Dahia; A Ahmed-Shuaib; R A Jacobs; S L Chew; J Honegger; R Fahlbusch; G M Besser; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

Review 4.  Sweating on the palm and sole: physiological and clinical relevance.

Authors:  Masato Asahina; Anupama Poudel; Shigeki Hirano
Journal:  Clin Auton Res       Date:  2015-04-17       Impact factor: 4.435

5.  Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors.

Authors:  V Perraudin; C Delarue; H Lefebvre; V Contesse; J M Kuhn; H Vaudry
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

6.  Several Circulating Biomarkers for PCOS Diagnosis.

Authors:  Peiqi Luo; Cheng Zhang; Yirui He; Gangyi Yang; Hua Liu; Ling Li
Journal:  Exp Clin Endocrinol Diabetes       Date:  2019-11-04       Impact factor: 2.949

Review 7.  Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Authors:  Ron T Gansevoort; Mustafa Arici; Thomas Benzing; Henrik Birn; Giovambattista Capasso; Adrian Covic; Olivier Devuyst; Christiane Drechsler; Kai-Uwe Eckardt; Francesco Emma; Bertrand Knebelmann; Yannick Le Meur; Ziad A Massy; Albert C M Ong; Alberto Ortiz; Franz Schaefer; Roser Torra; Raymond Vanholder; Andrzej Więcek; Carmine Zoccali; Wim Van Biesen
Journal:  Nephrol Dial Transplant       Date:  2016-01-29       Impact factor: 5.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.